Inhibrx Biosciences, Inc. (INBX) Earnings History
Annual and quarterly earnings data from 2016 to 2025
Loading earnings history...
INBX EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
INBX Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 0.0% | -10386.5% | -10773.5% |
| 2024 | -1042.5% | -165724.0% | 843786.0% |
| 2023 | 33.8% | -12178.9% | -13408.9% |
| 2022 | -4926.7% | -5890.4% | -6625.3% |
| 2021 | 62.3% | -1074.6% | -1147.6% |
Download Data
Export INBX earnings history in CSV or JSON format
Free sign-in required to download data
Inhibrx Biosciences, Inc. (INBX) Earnings Overview
As of May 8, 2026, Inhibrx Biosciences, Inc. (INBX) reported trailing twelve-month net income of -$140M, reflecting -107.8% year-over-year growth. The company earned $-9.04 per diluted share over the past four quarters, with a net profit margin of -10773.5%.
Looking at the long-term picture, INBX's historical earnings data spans multiple years. The company achieved its highest annual net income of $1.69B in fiscal 2024.
Inhibrx Biosciences, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including IMVT (-$464M net income), ARQT (-$2M net income, -4.3% margin), KYMR (-$315M net income, -794.4% margin), INBX has comparable earnings metrics. Compare INBX vs IMVT →
INBX Earnings vs Peers
Earnings metrics vs comparable public companies
INBX Historical Earnings Data (2016–2025)
10 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$140M | -108.3% | -$135M | $-9.04 | -10773.5% | -10386.5% |
| 2024 | $1.69B | +799.2% | -$331M | $116.58 | 843786.0% | -165724.0% |
| 2023 | -$241M | -66.2% | -$219M | $-5.12 | -13408.9% | -12178.9% |
| 2022 | -$145M | -77.6% | -$129M | $-3.62 | -6625.3% | -5890.4% |
| 2021 | -$82M | -8.1% | -$77M | $-2.15 | -1147.6% | -1074.6% |
| 2020 | -$76M | -47.2% | -$67M | $-2.99 | -590.5% | -526.6% |
| 2019 | -$51M | -64.9% | -$44M | $-1.41 | -565.3% | -480.7% |
| 2018 | -$31M | -60.3% | -$30M | $-1.15 | -415.5% | -393.5% |
| 2017 | -$19M | -135.1% | -$20M | $-0.68 | -244.6% | -248.2% |
| 2016 | -$8M | - | -$12M | $-0.23 | -124.0% | -182.2% |
See INBX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs INBX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare INBX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonINBX — Frequently Asked Questions
Quick answers to the most common questions about buying INBX stock.
Is INBX growing earnings?
INBX EPS fell to $-9.04, with earnings declining -107.8%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-140M.
What are INBX's profit margins?
Inhibrx Biosciences, Inc. net margin is -10773.5%, with operating margin at -10386.5%. Below-average margins reflect competitive or cost pressures.
How consistent are INBX's earnings?
INBX earnings data spans 2016-2025. The declining earnings trend is -107.8% YoY. Historical data enables comparison across business cycles.